Mar 26, 2024

Major shareholder announcement: The Capital Group Companies Inc.

With reference to Section 30 of the Danish Capital Market Act, Gubra A/S has been informed that the Capital Group Companies has acquired shares and crossed the 5% threshold for voting rights and share capital in Gubra A/S.

The Capital Group Companies Inc. now holds 959.625 of the voting rights in Gubra A/S (5.87% of total voting rights) and SMALLCAP World Fund, Inc. holds the holds the corresponding number of shares (5.87% of the total share capital).

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See www.gubra.dk for more information.